News Article | May 17, 2017
— Global Forehead Thermometer Market report covers product scope, market overview, opportunities, risk, and driving force. It analyzes the top manufacturers of Forehead Thermometer, with sales, revenue, and price in 2016 and 2017. It also display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017. Companies profiled in this research report are Braun, Microlife, Radiant, Jinxinbao, Easywell Bio, Dongdixin, AViTA, GEON Corp, Rossmax, Omron, Briggs Healthcare, Tecnimed srl, Exergen Corp, SAMICO, American Diagnostic Corp, Innovo, Vive Health, Oricom and Welch Allyn. Access this report at https://www.themarketreports.com/report/global-forehead-thermometer-market-by-manufacturers-countries-type-and-application-forecast-to-2022 To provide the historical development this report includes global market by regions, with sales, revenue and market share of Forehead Thermometer, for each region, from 2012 to 2017 and market analysis by type and application, with sales market share and growth rate by type, application, from 2012 to 2017. This report also analyze the key regions, with sales, revenue and market share by key countries in North America, Europe, Asia-Pacific, South America, and Middle East and Africa. Later, this report provides Forehead Thermometer Market forecast, by regions, type and application, with sales and revenue, from 2017 to 2022. In addition to above this report includes Forehead Thermometer sales channel, distributors, traders, dealers, and sum up with research findings and conclusion. Purchase this premium report at: https://www.themarketreports.com/report/buy-now/520918 Market Analysis by Regions • North America (USA, Canada and Mexico) • Europe (Germany, France, UK, Russia and Italy) • Asia-Pacific (China, Japan, Korea, India and Southeast Asia) • South America (Brazil, Argentina, Columbia etc.) • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Inquire about this report at: https://www.themarketreports.com/report/ask-your-query/520918 For more information, please visit https://www.themarketreports.com/report/global-forehead-thermometer-market-by-manufacturers-countries-type-and-application-forecast-to-2022
News Article | May 16, 2017
Blood collection tube is made up of disinfected glass or plastic tube with a closure that is evacuated to create a vacuum inside the tube to enable the suction of a predetermined volume of liquid. These tubes are most commonly used to collect blood samples, but can also be used as urine collection tubes and as serum separator tubes. Blood collection tubes are essential for diagnostics, in surgeries and for transfusion procedures. The Blood collection tubes are segmented according to tube type as plasma separation tube, heparin tubes, serum separating tubes, EDTA tubes, rapid serum tubes and others. The serum separating tubes has the largest market share followed by EDTA tubes. It is due to factors such as higher number of serum samples collected and used for various diagnostic applications. The key drivers influencing the growth of blood collection increase in aging population and widespread of diseases. The increasing government initiatives and rise in the number of surgical procedures are also helping to fuel the market growth. The developing cell therapies are a major opportunity for the players in this market. The key constraint of this market is the cost of blood handling equipment. North America is the largest market for blood collection tubes. The factors influencing the growth are increased level of awareness, government support and advancements in blood collection technologies. The key companies operating in this market are Becton, Dickinson & Company, Greiner Group AG, Sarstedt AG & Co., QIAGEN N.V., Terumo Corporation and FL Medical srl. 1. Introduction to the Blood Collection Tubes Market 2. Executive Summary 3. Market Analysis of Blood Collection Tubes 4. Global Blood Collection Tubes Market Analysis By Tube Type 5. Global Blood Collection Tubes Market Analysis By Region 6. Competitive Landscape of the Blood Collection Tubes Companies 7. Company Profiles of Blood Collection Tubes Industry For more information about this report visit http://www.researchandmarkets.com/research/t6b5zn/global_blood To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-blood-collection-tubes-market-2022key-companies-are-becton-dickinson--company-greiner-group-sarstedt-ag--co-qiagen-nv-terumo-corporation-and-fl-medical-300458318.html
News Article | April 19, 2017
The global mammography market is expected to reach a value of USD 3.8 billion by 2025 The market growth can be attributed to the rising initiatives by various governments and NGOs to raise awareness about early diagnosis of microcalcifications in breast tissue. Some significant organizations such as the National Breast Cancer Foundation, CDC, and Breast Cancer Organization are promoting the early diagnosis of mammary gland calcification, which is one of the crucial factors expected to drive the demand over the forecast period. Based on a report published by the National Cancer Institute in 2015, it was stated that the proportion of women aged 45 to 65 years had increased to 81.1% in breast cancer screening. Major mammography manufacturers are introducing new products and increasing the number of approved products, which is further expected to impel the demand in the coming years. In January 2016, FDA approved a new manual for digital mammography quality control by the American College of Radiology. The growing number of awareness campaigns to promote womens' health services is also anticipated to propel growth. Some of the key industry players are Fujifilm; Hologic; Philips Healthcare; Siemens Healthineers; Toshiba Medical Systems Corporation; GE Healthcare; Metaltronica; PLANMED OY; Mindray Medical International Limited; and IMS srl. Further Key Findings From the Study Suggest: Key Topics Covered: 1 Research Methodology 2 Executive Summary 3 Mammography Market Variables, Trends& Scope 3.1 Market Segmentation& Scope 3.2 Penetration & Growth Prospect Mapping 3.3 Mammography - SWOT Analysis, by Factor (Political & Legal, Economic and Technological) 3.4 Industry Analysis - Porter's 4 Market Categorization 1: Product Type Estimates & Trend Analysis 4.1 Mammography Market: Product Type Movement Analysis 4.2 Film Screen Systems 4.3 Digital Systems 4.4 Analog Systems 4.5 Biopsy Systems 4.6 3D Systems 5 Market Categorization 2: Technology Estimates & Trend Analysis 5.1 Mammography Market: Technology Movement Analysis 5.2 Breast Tomosynthesis 5.3 CAD 5.4 Digital 6 Market Categorization 3: Regional Estimates & Trend Analysis, by Product Type & Application 7 Competitive Landscape For more information about this report visit http://www.researchandmarkets.com/research/756bhj/mammography Research and Markets Laura Wood, Senior Manager email@example.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-38-billion-mammography-film-screen-systems-digital-systems-analog-systems-biopsy-systems-3d-systems-market-analysis-2013-2017--2025---research-and-markets-300441179.html
Agency: European Commission | Branch: FP7 | Program: BSG-SME | Phase: SME-2011-1 | Award Amount: 1.49M | Year: 2011
The recent explosion of GPU (Graphical Processing Unit) power has not been fully utilised by many SMEs, possibly because GPU programming requires specialist skills different from those of conventional programming. GPSME will provide the SME participants with a simple route to accessing GPU power. Each of the SME participants is facing increasing competition in the market and GPSME will allow them to greatly improve their products in terms of speed and quality without major overheads. By involving close cooperation between the SMEs and RTD performers, GPSME will develop a toolkit to automate the conversion of existing sequential CPU code to an optimal GPU implementation. With such a toolkit, the SMEs will be able to convert their existing CPU code without committing significant effort and time. It will also support the execution of advanced techniques within acceptable runtimes and hence allow the SMEs to use more complex computing models in their new products. This will bring them major commercial benefits and significantly improve their market positions. Technically, GPSME features techniques to adapt automatic parallelization to the latest GPU compute architecture to deliver optimal performance. This is expected to greatly improve on traditional CPU-based automatic parallelization. The literature review has suggested that the techniques in this area are still very much in their infancy and that there is no existing toolkit that can benefit the SMEs immediately. The application areas of the SME participants are widely differing, so GPSME will produce a breakthrough that will open the door for great performance gains across many areas of application. This development will be particularly suitable for SMEs that focus applications on moderate platforms. In the long term, the outcomes of GPSME will benefit many companies and improve industrial competitiveness across the whole European Union.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2009.5.4 | Award Amount: 1.16M | Year: 2010
The musculoskeletal apparatus is probably the organ system where the need for the integrative approach advocated by the Virtual Physiological Human (VPH) initiative is most pronounced. The neuromotor control involves the entire body, whereas the processes involved in muscle twitching, bones and muscle adaptation, musculoskeletal aging, and in most musculoskeletal diseases take place at the molecular level. The traditional reductionist approach is reaching dead ends in a number of relevant questions in musculoskeletal research, such as those related to osteoporotic fractures, the pathophysiology of growth in cerebral palsy children, the pathogenesis of rheumatoid arthritis and osteoarthritis, etc. It is becoming more and more evident that the way out is the development of new Information and Communication Technology (ICT) that makes personalised, predictive, and integrative musculoskeletal medicine possible. Worldwide, the two largest research projects focused on this are the Osteoporotic Virtual Physiological Human (VPHOP) integrated project funded by the European Commission, and the Center for Physics-based Simulation of Biological Structures (SIMBIOS) funded by the USA National Institute of Health. Both projects are targeting the same strategic objective, but each project breaks it into research goals that are overlapping in a few cases and complementary in all the others. This unique condition creates an extremely interesting opportunity for international collaboration, which drastically increases the international impact of the work being done by the VPHOP project, and produces the conditions for global cooperation on this grand challenge of biomedical research. With the Neuro Musculo Skeletal Physiome (NMS Physiome) project, the SIMBIOS and VPHOP consortia intend to establish a more organic cooperation, structured around three objectives: integrate the project communities, integrate the projects tools, and work collaboratively on grand challenges.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2009.5.2 | Award Amount: 4.97M | Year: 2010
Osteorthritis (OA) is a disabling disease, affecting the joints of 40% or more of the population over 60, resulting in a socioeconomic burden of 7b. per year in Germany alone. Joint surgery attempts to address the various disease stages, to either minimize the risk of early degeneration of the native joint, or to replace a fully degenerated joint, with well over 1,000,000 surgeries performed annually in the EU. Adequate joint function and longevity are the most important factors that define success, yet at least 10% of reconstructions fail within 10 years of surgery, and a large fraction of native joints progresses to early OA. The ensuing revision surgery is not only painful and stressful for the patient but also costly for the health care providers. Joint failure is a consequence of inadequate competence of the patients musculoskeletal system, joint overload and instability, or their combination. Currently, surgeons rely on 2D static radiographs and their experience to plan the procedure. To prevent failures and improve outcome, key facts on the mechanical conditions of the joint need to be available to the surgeon. By implementing refined image reconstruction, biomechanical modelling and analysis tools, MXL will make the dynamic joint loading and stability accessible for the planning of joint surgery in every case. Based on this technology, MXL safeguards the patient by supporting the surgeon to decide when to operate, which procedure to use, and which key aspects to address to reduce the failure rate and improve the functional outcome of joint surgery. Therefore, we will develop an ICT based planning environment that provides the surgeon with quantitative information on the patients anatomy, the competence of the soft and hard tissues, and integrates them within biomechanical models to arrive at an optimal strategy for joint surgery. This will result in a breakthrough with tremendous effects on patient safety and the return of function and joint longevity.
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ICT-2009.5.4 | Award Amount: 1.33M | Year: 2010
In recent years, various terms the Virtual Physiological Human (VPH), Integrative Biology, Physiome Research have been used to describe the trend in biomedical research towards the consideration of systemic processes. These phenomena are commonly observed in living organisms but cannot be explained within a single sub-system but reflect, rather, systemic outcomes that result from the interaction of multiple sub-systems.\nTraditionally, when confronted by the complexity exhibited in biomedical problems, researchers have been forced to focus purely on individual sub-systems; the most common boundary separating these has been spatiotemporal scale. The current interest in VPH is demanding greater concentration on the study and simulation of biological systems at multiple scales, and multiscale data collection and multiscale modelling have recently become synonymous with integrative research. The many VPH projects that will start to demand multiscale visualisation in the coming years suggests that this area should receive urgent attention.\nThe Multiscale Spatiotemporal Visualisation (MSV) project aims, by international cooperation between the European @neurIST and VPHOP integrated projects, the US National Alliance for Medical Imaging Computing (NA-MIC), and the New Zealand-based IUPS Physiome initiative: i) to define an interactive visualisation paradigm for biomedical multiscale data, ii) to validate it on the large collections produced by the VPH projects, and iii) to develop a concrete implementation as an open-source extension to the Visualisation Took Kit (VTK), ready to be incorporated by virtually any biomedical modelling software project.
News Article | February 10, 2017
SOUTHBOROUGH, Mass., Feb. 10, 2017 (GLOBE NEWSWIRE) -- Sevcon, Inc. (Nasdaq:SEV), a world leader in the design and manufacture of controls for zero emission electric and hybrid vehicles, today announced that it will release first quarter 2017 financial results after the close of the market on Tuesday, February 14, 2017. Sevcon will host a conference call to discuss the results on Wednesday, February 15, 2017 at 9:00 a.m. ET. President and Chief Executive Officer Matt Boyle and Vice President, Treasurer and Chief Financial Officer Paul Farquhar will host the call. Those who wish to listen to the conference call webcast should visit the Investor Relations section of the company’s website at www.sevcon.com. The live call can also be accessed by dialing (877) 407-5790 or (201) 689-8328 prior to the start of the call. If you are unable to listen to the live call, the webcast will be archived on the company’s website. Sevcon is a global supplier of control and power solutions for zero-emission, electric and hybrid vehicles. Its products control on- and off-road vehicle speed and movement, integrate specialized functions, optimize energy consumption and help reduce air pollution. Sevcon’s Bassi Division produces battery chargers for electric vehicles; power management and uninterrupted power source (UPS) systems for industrial, medical and telecom applications; and electronic instrumentation for battery laboratories. The company supplies customers from its operations in the U.S., U.K., France, Germany, Italy, Canada, China and the Asia Pacific region, as well as through an international dealer network. Visit www.sevcon.com and www.bassi-srl.eu.
News Article | February 14, 2017
SOUTHBOROUGH, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Sevcon, Inc. (Nasdaq:SEV) reported financial results for the first quarter of fiscal 2017 ended December 31, 2016. “First-quarter revenues increased 38% year over year, reflecting the $5.2 million contribution from our Bassi acquisition, partially offset by lower sales from the industrial side of the business due to a continuation of the challenging macroeconomic headwinds our customers are facing,” said Sevcon Chief Executive Officer Matt Boyle. “Bassi has performed above our expectations, having reported 33% revenue growth post acquisition compared with the same three-month period in the prior year, and we expect that momentum to continue in the second quarter.” “During the first quarter, sales to on-road customers were up 25% compared with last year, due to demand in Europe for two wheel vehicles and additional revenues from engineering services associated with two on-road projects, respectively. Sales in both the two-wheel and four-wheel sectors increased by double-digits, although this business will continue to fluctuate from quarter to quarter due to the timing of orders as we ramp up development and production activities.” “Comparing Q1 2017 with Q1 2016, we were negatively impacted by a combination of factors that adversely affected gross profit. Sales mix, predominately the increase in Bassi sales offset by lower industrial market revenues, lowered gross profit by approximately $1.1 million. Following a change of requirements by a customer, we recognized $500,000 of potential additional costs against one project and we are currently renegotiating the scope of this project. Foreign currency fluctuations reduced reported gross profit by approximately $300,000, mainly due to a stronger U.S. dollar compared with both the British pound and the euro than in the prior-year period.” “After the close of the first quarter, we announced a project to provide a bespoke drivetrain to a Sino/European OEM -- Sevcon's sixth major project in the development pipeline. The agreement contains two near-term milestones, including the initial product sample and proof-of-concept in the current second quarter of fiscal 2017, and performance testing in the customer's vehicle in the fourth quarter of fiscal 2017.” “We remain very bullish about our prospects this year. While we expect challenging conditions in the industrial markets in the near-term, we expect to see further improvement in our on-road business as a result of our strong project pipeline. We are excited by the confidence that an increasing number of on-road OEMs are placing in our solutions, and we look forward to meeting the many milestones we have before us in 2017. As we look even further out, our project pipeline and the market demand for electrification solutions provides us with significant opportunity for growth.” Revenues increased to $12.5 million in the first quarter of fiscal 2017 from $9.1 million in the first quarter of fiscal 2016, reflecting $5.2 million in revenues from Bassi. Excluding Bassi, revenues were $1.7 million lower than in the prior-year period, reflecting continued weakness on the industrial side of the business. Foreign currency fluctuations decreased reported sales in the first fiscal quarter by $0.9 million, or 10.4%. Sevcon has scheduled a conference call to review its results for the first quarter tomorrow, February 15, 2017, at 9:00 a.m. ET. Those who wish to listen to the conference call webcast should visit the investor relations section of the company’s website at http://ir.sevcon.com. The live call also can be accessed by dialing (877) 407-5790 or (201) 689-8328 prior to the start of the call. If you are unable to listen to the live call, the webcast will be archived on the company’s website. Sevcon uses EBITDA and adjusted EBITDA, which are non-GAAP financial measures, in this news release. The Company reports these metrics because they are key measures used by its management and Board of Directors to evaluate the ongoing performance of the business and to develop short and long-term operational plans. Accordingly, the Company believes that EBITDA and adjusted EBITDA provide useful information to investors and others in understanding and evaluating Sevcon’s operating results in the same manner as its management and Board of Directors. Statements in this release about the Company’s anticipated financial results and growth, as well as those about the development of its products and markets, including without limitation, statements about the benefits that may be obtained from certain customer contracts, are forward-looking statements that are based on management’s present expectations and involve risks and uncertainties that could cause actual results to differ materially from those projected. Important factors that could cause these statements not to be realized include that we may not be able to successfully integrate and manage the Bassi business, the Bassi acquisition may not further our business strategy or results as we expect, we may not be able to successfully complete the development of the controllers contracted by particular customers, the manufacturers for whom we are performing development work may decide not to commence production or purchase from us, and the markets for the particular vehicles may not develop as the manufacturers hope. Additional important factors are set forth under “Risk Factors” and elsewhere in the Forms 10-K and 10-Q we file with the SEC. Sevcon is a global supplier of control and power solutions for zero-emission, electric and hybrid vehicles. Its products control on- and off-road vehicle speed and movement, integrate specialized functions, optimize energy consumption and help reduce air pollution. Sevcon’s Bassi Division produces battery chargers for electric vehicles; power management and uninterrupted power source (UPS) systems for industrial, medical and telecom applications; and electronic instrumentation for battery laboratories. The company supplies customers from its operations in the U.S., U.K., France, Germany, Italy, Canada, China and the Asia Pacific region, as well as through an international dealer network. Visit www.sevcon.com and www.bassi-srl.eu.
News Article | March 3, 2017
Following the fraudulent sale of 31 Solar PV power plants to EAM Solar ASA in July 2014 by Enovos Luxembourg SA and Avelar Energy Ltd through their jointly owned special purpose vehicle Aveleos SA of Luxembourg, the so-called "P31 Acquisition", EAM group has been forced to pursue EAM's legal and economic rights in several legal venues due to the unwillingness of the sellers to respect their contractual obligations in accordance with the Share Purchase Agreement entered into the 31st of December 2013. The financial reporting through annual and quarterly reports issued since July 2014 contains further details relevant for the interpretation of this stock exchange notice and can be found on the company web site (www.eamsolar.no). 1) Breach of standstill agreement proceedings against Aveleos SA in the Court of Luxembourg In October 2014, EAM entered into a so-called standstill agreement with Aveleos SA that also encompassed Enovos, Avelar and its employees. The purpose of the standstill agreement was to give the sellers time to resolve the payment suspension measures of GSE and to document the necessary facts confirming the validity of the FIT contracts and the technical feasibility of the power plants within a limited time frame of 6 months. In exchange for this the sellers pledged to finance the running costs of the criminally affected power plants with a minimum of EUR 5 million in liquidity until the above matters was resolved. In exchange for this pledge and the promises given by the sellers, EAM lifted the injunction achieved on the bank accounts of Aveleos SA in Luxembourg in September 2014 in order to avoid the immediate bankruptcy of Aveleos SA in October 2014 as threatened by the Enovos and Avelar directors. Aveleos and its Directors breached the standstill agreement already in November 2014, as confirmed in the ruling by the Civil Court of Milan (Enterprise Matters Specialized Section) in September 2015 and by the Criminal Court of Milan in the ruling the 13th of September 2016. In the Autumn 2015 Aveleos summoned EAM again in Luxembourg court in order to misuse the standstill agreement to achieve exclusion from the criminal proceedings in Milan in order for Enovos and Avelar to escape legal proceedings. On the 20th of September 2016 Aveleos asked the court of Luxembourg for a postponement of these proceeding, which was granted until January 2017. The first hearing in the Standstill Agreement procedures in Luxembourg took place on 17 January 2017. Both parties filed their note of pleadings and presented to the judge. In the proceedings Aveleos SA has delivered a claim and EAM Solar ASA a counter-claim. In a ruling communicated yesterday the court decided that the Luxembourg civil proceedings regarding the Standstill Agreement shall be put to a halt until the arbitration award before the Court of Milan is rendered i.e. all claims of Aveleos have been suspended until further. 2) Defamation case - allegations of false complaint to be tried in the Luxembourg District Court The companies EAM Solar ASA and EAM Solar Italy Holding srl, as well as their CEO and Managing Director, Mr Viktor E. Jakobsen, received in January 2017 a subpoena to meet in court in Luxembourg on 13 March 2017. The plaintiffs are Enovos Luxembourg SA, Enovos International SA and their directors. The plaintiffs claim that the criminal complaint filed by EAM Solar ASA in February 2016 is false and not merited. This is an attempt by the directors to evade the ongoing investigation by the criminal court of Luxembourg that followed after the criminal complaint was filed. In a communication received yesterday we have been informed that the case will not be heard until the Prosecutor's Office have decided on the criminal complaint filed in February 2016 that is still in their hands. Therefore, the case will not be pleaded on March 13, 2017 and will be rescheduled. About EAM Solar: EAM Solar is a utility company that acquires and operates solar power plants. The Company currently owns solar PV power plants in Italy. The plants are operating under long-term sales contracts. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.